After Novartis’ Pluvicto shook up iSpot.TV’s monthly rankings of the top TV advertising spenders in pharma to kick off the year, it was back to business as usual in February. AbbVie’s ...

Pharma giant AbbVie has been taken to task by the FDA for running an ad for one of its migraine drugs, featuring tennis star Serena Williams, which the agency says overstates its efficacy.

For his work in 2024, AbbVie helmsman Robert Michael—who took over as CEO from Richard Gonzalez on July 1—collected nearly $18.5 million in total pay.

AbbVie (ABBV) closed the latest trading day at $213.59, indicating a -1.42% change from the previous session's end. The stock fell short of the S&P 500, which registered a loss of 0.76% for the day.

Pharmaceutical giant AbbVie has filed a lawsuit against Genmab, claiming the Denmark-based drugmaker, who is also a commercial oncology partner with the North Chicago-based company, knowingly ...

The latest price target for AbbVie (NYSE:ABBV) was reported by Wells Fargo on March 5, 2025. The analyst firm set a price target for $240.00 expecting ABBV to rise to within 12 months (a possible ...

AbbVie was downgraded to "Hold" due to high debt, fluctuating earnings, and declining Humira sales, but the stock outperformed with a 31% return since July 2024. Despite mixed quarterly results ...